<DOC>
	<DOCNO>NCT00334906</DOCNO>
	<brief_summary>The purpose study characterize progression disease use volumetric MRI technique cognitive outcome measure patient moderate dementia Alzheimer 's type treat open-label memantine .</brief_summary>
	<brief_title>Study Memantine Assessment Selected Measures Volumetric Magnetic Resonance Imaging ( MRI ) Cognition Moderate AD ( Alzheimer 's Disease )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Ambulatory male female patient least 50 year age ( female least 2 year postmenopausal ) A diagnosis probable AD [ accord National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Associations ( NINCDSADRDA ) criteria ] moderate severity [ MiniMental State Examination score 15 20 , inclusive ] On stable dose Food Drug Administration ( FDA ) approve acetylcholinesterase inhibitor Current Diagnostic Statistical Manual Mental DisordersFourth Edition ( DSMIV ) Axis I disorder AD Previous image result consistent diagnosis AD Modified Hachinski Ischemia Score great 4 Evidence neurologic disorder Inability participate MRI test No clinically significant systemic disease A know suspected history alcohol drug abuse past 10 year Taking excluded medication Previous treatment commercial memantine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>memantine</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>MRI</keyword>
	<keyword>moderate Alzheimer 's disease</keyword>
</DOC>